Sumedha Roy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sumedha Roy has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Anton Belousov
F. Hoffmann-La Roche Ltd, Basel, Switzerland
10 shared publications - Brendan C. Bender
Genentech Inc., South San Francisco, California
10 shared publications - Chi-Chung Li
Genentech, Inc., South San Francisco, CA 94080, USA
10 shared publications - David C. Turner
Clinical Pharmacology Genentech South San Francisco California USA
10 shared publications - Kendra K. Radtke
Genentech Inc., South San Francisco, California
10 shared publications - Zao Li
Genentech Inc., South San Francisco, California
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.
- Open Access
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Selected Cytokine Concentration-Time Profiles for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of T-Cell Engaging Bispecific Antibodies (T-BiSp): Molecule Format, Dosing Schedule, Hospitalization, and Premedication
- Open Access
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Summary of CRS Occurrence by Step-Up Dose Fractions for Approved T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Open Access
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- 17 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Overview of CRS Occurrence, Dosing Regimens, and Exposure Metrics for Exposure-Response Analyses of T-Cell Engaging Bispecific Antibodies (T-BiSp)
- Top Cited PapersOpen Access
- 18 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (2) , 245-257
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.
- 18 November 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (2) , 245-257
Top Cited PapersOpen AccessClinical Pharmacology of Cytokine Release Syndrome with T-Cell–Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies
Cytokine release syndrome (CRS) is a common acute toxicity in T-cell therapies, including T-cell–engaging bispecific antibodies (T-BiSp). Effective CRS management and prevention are crucial in T-BiSp development. Required hospitalization for seven of the nine approved T-BiSp and the need for clinical intervention in severe cases highlight the importance of mitigation strategies to reduce health care burden and improve patient outcomes. In this review, we discuss the emerging evidence on CRS mitigation, management, and prediction. We cover different strategies for dose optimization, current and emerging (pre) treatment strategies, quantitative pharmacology tools used during drug development, and biomarkers and predictive factors. Insights are gleaned on step-up dosing and formulation effects on CRS and CRS relationships with cytokine dynamics and drug levels gathered through a review of T-BiSp licensing applications and emerging data from conferences and publications.